entertainment -WSS

entertainment

author：comprehensive 2025-09-29 21:13:04 - browse：8918

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： WATCH: Why do fingernails fall off when they're damaged?

focus

WSS

Readout Newsletter: Zepbound, Valneva's vaccine, and more

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Disclosing genetic information: not as worrisome as once feared

Carbon Health diabetes program, a test of data

#NeedHerScience: shining a light on gender disparities in medicine

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

hotspot

entertainment

entertainment

Virginia high school admissions case could be legal follow

What health policies could hitch a ride on a spending bill?

Dobbs anniversary: the lost opportunity of abortion as health care

Donald Trump's relentless attacks on special counsel Jack Smith

What does generative AI mean for health care? We asked experts

Why we need to separate burnout from moral injury in health care

In age of alternative facts, a scholarly course on calling out crap

The strategy behind pharma's lawsuits over drug pricing reform

Continuity nursing helped my family in our darkest PICU moments

CVS, Rite Aid closures threaten to worsen pharmacy deserts

leisure time

NIH chief: government has fallen behind pharma on clinical trials

A letter from the executive editor: STAT UnitedHealth investigation

Weight loss drugs should be covered by insurers, AMA says

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

In areas with more Black doctors, Black people live longer

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

entertainment

hotspot

focus

hotspot